Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 16/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764445 | 0.91 | EGFR (0.48) | AURKARPS6KB1EGFRAURKBERBB2 | |
| SCHEMBL4774248 | 0.90 | AURKA (0.51) | CHUKAURKARPS6KB1EGFRAURKB | |
| SCHEMBL4772569 | 0.86 | EGFR (0.50) | CHUKAURKARPS6KB1EGFRAURKB | |
| SCHEMBL4769248 | 0.85 | EGFR (0.56) | CHUKAURKARPS6KB1EGFRERBB2 | |
| SCHEMBL4763823 | 0.85 | EGFR (0.49) | AURKARPS6KB1EGFRERBB2ERBB4 | |
| SCHEMBL4763951 | 0.82 | EGFR (0.58) | AURKARPS6KB1EGFRERBB2 | |
| SCHEMBL4718830 | 0.82 | EGFR (0.51) | AURKARPS6KB1EGFRAURKBERBB2 | |
| SCHEMBL4764461 | 0.81 | EGFR (0.52) | AURKARPS6KB1EGFRAURKBERBB2 | |
| SCHEMBL4766773 | 0.81 | EGFR (0.47) | AURKARPS6KB1EGFRAURKBERBB2 | |
| SCHEMBL4766340 | 0.79 | EGFR (0.48) | AURKARPS6KB1EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101560214-A | 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2009-10-21 | — | — | CN | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| CN-1538847-A | 4-amino-6-phenyl-pyrrolo [2, 3-d ] pyrimidine derivatives | ��˹��ŵ�� | 2004-10-20 | — | — | CN | claimed |
| CN-101560214-B | 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives | NOVARTIS AG | 2011-05-25 | — | — | CN | disclosed |
| CN-101560214-A | 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2009-10-21 | — | — | CN | disclosed |
| US-7390805-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-06-24 | — | — | US | disclosed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-7323469-B2 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | disclosed |
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | BOLD GUIDO | 2007-07-12 | — | — | US | disclosed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | disclosed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | TYMP, DPYD, CCND2 | CHUK 866/4885AURKA 444/4885RPS6KB1 677/4885 |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | CHUK 1360/4885AURKA 1206/4885RPS6KB1 761/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | CHUK 1012/4885AURKA 875/4885RPS6KB1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.